BioSpace News Archive

Bio-Techne Corporation (NASDAQ:TECH) is at the forefront of coronavirus disease 2019 (COVID-19) and SARS-CoV-2 research. This is evidenced by the large number of published research papers on the subject that have cited Bio-Techne products, including the breakthrough Cell paper by Hoffmann et al ., which used the R&D Systems ™ -br

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders [09-June-2020] OXFORD, England , June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreeme

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase 2, CALVID-1 clinical trial o

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today announced the pricing of $850 million aggregate principal amount of 2.000% exchangeable senior notes due 2026 in a private offering (the “offering”) by Jazz Investments I Limited, its wholly-owned subsidiary (the “Issuer”), to qualified institutional buyers pursuant to Ru

Intersect ENT®, Inc. (Nasdaq: XENT), , today announced that the Centers for Medicare and Medicaid Services (CMS) has approved SINUVA® (mometasone furoate) Sinus Implant for transitional pass-through payment status for reimbursement under the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgery Center Payment System

C2i Genomics (“C2i”), a company dedicated to improving cancer patient lives and outcomes with a breakthrough tumor pattern recognition approach for liquid biopsy, today announced that it has raised $12 million in its Series A financing. The financing was led by Casdin Capital and joined by additional new investors including NFX Capital, The Mark Foundation for Cancer Research and other investors. Proceeds from the financing will

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that in response to Can-Fite’s Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the FDA has provided detailed comments regarding the prospective use of Piclidenoson to treat patients suffering from COVID-19.

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session

Crown Bioscience announced the presentation of new, proprietary NAFLD/NASH preclinical model development data.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced it has completed enrollment of 119 patients in the clinical trial evaluating HEPLISAV-B® [Hepatitis B Vaccine, Adjuvanted] in adults with end-stage renal disease who are initiating or undergoing hemodialysis.